RECRUITING

Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., presupplementary motor area) thought to aid in memory will improve verbal retrieval in multiple sclerosis patients. The primary outcome measures are neuropsychological assessments of verbal retrieval, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (EEG) measures. Additionally, the study will examine the degree to which baseline assessments of cognition and concussion history predict responses to treatment over time, both on assessments administered within the intervention period and at follow-up.

Official Title

Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation

Quick Facts

Study Start:2023-10-18
Study Completion:2027-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05958381

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. * dementia of any type
  2. * epilepsy or other seizure disorders
  3. * severe traumatic brain injury
  4. * brain tumor
  5. * present drug abuse
  6. * stroke
  7. * blood vessel abnormalities in the brain
  8. * Parkinson's disease
  9. * Huntington's disease
  10. * anti-convulsants
  11. * L-dopa
  12. * carbamazepine
  13. * sulpiride
  14. * pergolide
  15. * lorazepam
  16. * rivastigmine
  17. * dextromethorphan
  18. * D-cycloserine
  19. * flunarizine
  20. * ropinirole
  21. * stimulants (dextroamphetamine/amphetamine/modafinil/armodafinil) must be stopped during enrollment

Contacts and Locations

Study Contact

Ashna Adhikari, MS
CONTACT
972-833-3161
Ashna.Adhikari@UTDallas.edu
Jill Ritter, BS
CONTACT
972-833-3161
jill.ritter@utdallas.edu

Principal Investigator

John Hart, Jr, MD
PRINCIPAL_INVESTIGATOR
University of Texas at Dallas

Study Locations (Sites)

The University of Texas at Dallas
Richardson, Texas, 75080
United States

Collaborators and Investigators

Sponsor: The University of Texas at Dallas

  • John Hart, Jr, MD, PRINCIPAL_INVESTIGATOR, University of Texas at Dallas

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-18
Study Completion Date2027-06-30

Study Record Updates

Study Start Date2023-10-18
Study Completion Date2027-06-30

Terms related to this study

Keywords Provided by Researchers

  • transcranial direct current stimulation (tDCS)
  • multiple sclerosis
  • electroencephalography (EEG)

Additional Relevant MeSH Terms

  • Multiple Sclerosis, Relapsing-Remitting